Internal tandem duplication (ITD) mutation in Fms-like tyrosine kinase 3 gene (FLT3/ITD) represents an unfavorable genetic change in acute myeloid leukemia (AML) and is associated with poor prognosis.

今日（1月18日），中国国家药监局药品审评中心（CDE）官网最新公示，第一三共（Daiichi Sankyo）申报的5.1类新药盐酸奎扎替尼片上市申请获得受理。公开资料显示，这是一款FLT3抑制剂Vanflyta（quizartinib），已经于2023年7月获美国FDA批准治疗带有FLT3-ITD突变阳性的新确诊急性髓系白血病（AML）成人患者，它用于AML患者三个治疗阶段——诱导、巩固和维持治 ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...

来自暨南大学附属第一医院血液科等多个机构的研究人员发现，敲低 CERT 能够抑制携带 FLT3-ITD 突变的 AML 细胞的生长，并促进其凋亡。将 CERT 抑制剂与 FLT3 抑制剂联合使用，对 FLT3-ITD 突变的急性髓系白血病细胞展现出协同作用。此外，HPA-12 与克瑞兰尼布 ...

AML 作为一种侵袭性血液恶性肿瘤，具有显著的生物学和临床异质性，精准的风险分层对优化治疗效果、减少治疗相关并发症至关重要。目前，细胞遗传学变化和基因突变已被用于风险分层，其中 NPM1 和 FLT3-ITD 是 AML 患者中最常见的复发性基因突变 。然而，对这些突变进行分子检测存在诸多挑战，如不同机构资源和实验室基础设施差异大，限制了检测的可及性，延长了检测周转时间。

Aptose Biosciences (NASDAQ:APTO;TSX:APS), a clinical-stage oncology stock, achieved positive safety and response results from ...

Around one-third of patients with acute myeloid leukemia (AML) harbor FLT3 gene mutations which are associated with poor prognosis and high risk of relapse. Several compounds targeting FLT3 internal ...

Daiichi Sankyo’s Vanflyta has become the first drug in the US to be approved for newly-diagnosed acute myeloid leukaemia (AML) with FLT3-ITD mutations, nearly four years after being rejected by ...

“We know how important MRD detection is, and will continue to be, in AML” said Adrian Smith, CEO, OGT. “Advances in the understanding of AML MRD, such as recent research studies highlighting the ...

NICE has recommended Vanflyta (quizartinib) for routine NHS commissioning as an induction, consolidation, and maintenance therapy for treating newly diagnosed FLT3-ITD-positive AML, an indication ...

The National Health Service (NHS) England has announced the routine commissioning of Daiichi Sankyo's quizartinib for acute ...